Phase 1 Trial to Study JANX013 and JANX007 Combination in mCRPC | stella

Learn Find trials matched to me

Learn Find trials matched to me →

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Privacy For Researchers Data Labs ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Phase 1 Trial to Study JANX013 and JANX007 Combination in mCRPC | stella

Back to Prostate Cancer trials

Opening soon

Plain-English translation of NCT07813637 on ClinicalTrials.gov ↗ · Source last updated September 2026 · How we translate trials

Read our Prostate Cancer research guide →

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

Key details

Phase

Safety & dosing

Sponsor

Janux Therapeutics

Enrollment target

~110 participants

Started

September 2026

Primary completion

July 2029

Age range

18 Years and older

Sex

View full record on ClinicalTrials.gov

Male only

Last updated on clinicaltrials.gov in September 2026.

Contact the research team directly

Reach out to the team running this trial. Response times vary — some teams are faster than others.

Central contact

Janux Therapeutics, MD

Janux Therapeutics

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.